Julen Oyarzabal

Integrating academic rigor with investment vision, he is a Partner and CSO at Columbus Venture Partners, following a distinguished career at UCSF, Johnson & Johnson, and CNIO. After leading Translational Sciences at CIMA, he has become a specialist in de-risking therapeutic development. With over 35 patent families and a key role as an expert for the European Medicines Agency (EMA), he now leverages his deep expertise in small-molecule design, synthetic biology and advanced therapies to identify and scale high-impact biotech innovations: from therapeutics to manufacturing.